


*Technologies for Managing Urinary
Incontinence*

July 1985

NTIS order #PB85-240208



HEALTH TECHNOLOGY CASE STUDY 33

Technologies for Managing Urinary Incontinence

JULY 1985

This case study was performed as part of OTA'S assessments:
**Federal Policies and the Medical Devices Industry
and
Technology and Aging in America**

Prepared for OTA by:
Joseph Ouslander, M.D.
UCLA School of Medicine
and
Robert Kane, M.D.
UCLA School of Medicine
with
Shira Vollmer
UCLA School of Medicine
and
Melvyn Menezes
School of Management, UCLA

OTA Case Studies are documents containing information on a specific medical technology or area of application that supplements formal OTA assessments. The material is not normally of as immediate policy interest as that in an OTA Report, nor does it present options for Congress to consider.



CONGRESS OF THE UNITED STATES
Office of Technology Assessment
Washington, D C 20510

Recommended Citation:

Ouslander, Joseph, Kane, Robert, Vollmer, Shira, and Menezes, Melvyn, *Technologies for Managing Urinary Incontinence* (Health Technology Case Study 33), OTA-HCS-33, Washington, DC: U.S. Congress, Office of Technology Assessment, July 1985. This case study was performed as part of OTA'S assessments of *Federal Policies and the Medical Devices Industry and Technology and Aging in America*.

Library of Congress Catalog Card Number 85-600554

For sale by the Superintendent of Documents
U.S. Government Printing Office, Washington, DC 20402

Preface

Technologies for Managing Urinary Incontinence is Case Study 33 in OTA'S Health Technology Case Study Series. This case study has been prepared in connection with two OTA projects: *Federal Policies and the Medical Devices Industry and Technology and Aging in America*. The former project, conducted by the Health Program, was requested by the House Committee on Energy and Commerce and its Subcommittee on Health and the Environment and the Senate Committee on Finance, Subcommittee on Health. The latter project, conducted by the Biological Applications Program, was requested by the House Select Committee on Aging, and the Senate Special Committee on Aging. A listing of other case studies in the series is included at the end of this preface, and endorsed by the House Committee on Education and Labor.

OTA case studies are designed to fulfill two functions. The primary purpose is to provide OTA with specific information that can be used in forming general conclusions regarding broader policy issues. The first 19 cases in the Health Technology Case Study Series, for example, were conducted in conjunction with OTA'S overall project on *The Implications of Cost-Effectiveness Analysis of Medical Technology*. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of cost-effectiveness or cost-benefit analysis, OTA was able to better analyze the potential contribution that those techniques might make to the management of medical technology and health care costs and quality.

The second function of the case studies is to provide useful information on the specific technologies covered. The design and the funding levels of most of the case studies are such that they should be read primarily in the context of the associated overall OTA projects. Nevertheless, in many instances, the case studies do represent extensive reviews of the literature on the efficacy, safety, and costs of the specific technologies and as such can stand on their own as a useful contribution to the field.

Case studies are prepared in some instances because they have been specifically requested by congressional committees and in others because they have been selected through an extensive review process involving OTA staff and consultations with the congressional staffs, advisory panel to the associated overall project, the Health Program Advisory Committee, and other experts in

various fields. Selection criteria were developed to ensure that case studies provide the following:

- examples of types of technologies by function (preventive, diagnostic, therapeutic, and rehabilitative);
- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (e.g., general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (e. g., cost);
- examples of technologies with associated high costs either because of high volume (for low-cost technologies) or high individual costs;
- examples that could provide information material relating to the broader policy and methodological issues being examined in the particular overall project; and
- examples with sufficient scientific literature.

Case studies are either prepared by OTA staff, commissioned by OTA and performed under contract by experts (generally in academia), or written by OTA staff on the basis of contractors' papers.

OTA subjects each case study to an extensive review process. Initial drafts of cases are reviewed by OTA staff and by members of the advisory panel to the associated project. For commissioned cases, comments are provided to authors, along with OTA'S suggestions for revisions. Subsequent drafts are sent by OTA to numerous experts for review and comment. Each case is seen by at least 30 reviewers, and sometimes by 80 or more outside reviewers. These individuals may be from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists, sociologists, decision analysts, biologists, and so forth, as appropriate, also review the cases.

Although cases are not statements of official OTA position, the review process is designed to satisfy OTA'S concern with each case study's scientific quality and objectivity. During the various stages of the review and revision process, therefore, OTA encourages, and to the extent possible requires, authors to present balanced information and recognize divergent points of view.

Health Technology Case Study Series^a

Case Study Series No.	Case study title; author(s); OTA publication number ^b	Case Study Series No.	Case study title; author(s); OTA publication number ^b
1	Formal Analysis, Policy Formulation, and End-Stage Renal Disease; Richard A. Rettig (OTA-BP-H-9(1)) ^c	18	The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ^d
2	The Feasibility of Economic Evaluation of Diagnostic Procedures: The Case of CT Scanning; Judith L. Wagner (OTA-BP-H-9(2))	19	Assessment of Four Common X-Ray Procedures; Judith L. Wagner (OTA-BP-H-9(19)) ^e
3	Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3))	20	Mandatory Passive Restraint Systems in Automobiles: Issues and Evidence; Kenneth E. Warner (OTA-BP-H-15(20)) ^f
4	Cost Effectiveness of Automated Multichannel Chemistry Analyzers; Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(4))	21	Selected Telecommunications Devices for Hearing-Impaired Persons; Virginia W. Stern and Martha Ross Redden (OTA-BP-H-16(21)) ^g
5	Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(5))	22	The Effectiveness and Costs of Alcoholism Treatment; Leonard Saxe, Denise Dougherty, Katharine Esty, and Michelle Fine (OTA-HCS-22)
6	The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications; Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6))	23	The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis; John C. Langenbrunner (Office of Technology Assessment) (OTA-HCS-23)
7	Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7))	24	Variation in Length of Hospital Stay: Their Relationship to Health Outcomes; Mark R. Chassin (OTA-HCS-24)
8	The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8))	25	Technology and Learning Disabilities; Candis Cousins and Leonard Duhal (OTA-HCS-25)
9	The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9))	26	Assistive Devices for Severe Speech Impairments; Judith Randal (Office of Technology Assessment) (OTA-HCS-26)
10	The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10))	27	Nuclear Magnetic Resonance Imaging Technology: A Clinical, Industrial, and Policy Analysis; Earl P. Steinberg and Alan Cohen (OTA-HCS-27)
11	Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11))	28	Intensive Care Units (ICUs): Clinical Outcomes, Costs, and Decisionmaking; Robert A. Berenson (OTA-HCS-28)
12	Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12))	29	The Boston Elbow; Sandra J. Tanenbaum (OTA-HCS-29)
13	Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13))	30	The Market for Wheelchairs: Innovations and Federal Policy; Donald S. Shepard and Sarita L. Karen (OTA-HCS-30)
14	Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14))	31	The Contact Lens Industry: Structure, Competition, and Public Policy; Leonard G. Schiffrin and William J. Rich (OTA-HCS-31)
15	Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15))	32	The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32)
16	The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16))	33	Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33)
17	Surgery for Breast Cancer: Karen Schachter Weingrod and Duncan Neuhauser (OTA-BP-H-9(17))	34	The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFries Thomas R. Oliver, and Irwin Litt (OTA-HCS-34)

^aavailable for sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC, 20402, and by the National Technical Information Service, 5285 Port Royal Rd., Springfield, VA, 22161. call OTA'S Publishing Office (224-8996) for availability and ordering information.

^boriginal publication numbers appear in parentheses.

^cThe first 17 cases in the series were 17 separately issued cases in *Background Paper #2: Case Studies of Medical Technologies*, prepared in conjunction with OTA'S August 1980 report *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

^d*Background paper #3 to The Implications of Cost-Effectiveness Analysis of Medical Technology.*

^e*Background paper #5 to The Implications of Cost-Effectiveness Analysis of Medical Technology.*

^f*Background paper #1 to OTA's May 1982 report Technology and Handicapped People.*

^g*Background Paper #2 to Technology and Handicapped People.*

OTA Project Staff for Case Study #33

Roger Herdman, *Assistant Director, OTA
Health and Life Sciences Division*

Clyde J. Behney, *Health Program Manager*

Jane E. Sisk, *Project Director*

Judith L. Wagner, *Senior Analyst*

Robert Harootyan, *Analyst*

David McCallum, *Senior Analyst*

Katherine E. Locke, *Research Assistant*

Brad Larson, *Research Assistant*

H. Christy Bergemann, *Editor*

Ginny Cwalina, *Administrative Assistant*

Rebecca I. Erickson, *Secretary/Word Processor Specialist*

Brenda Miller, *Word Processor/P. C. Specialist*

Diann G. Hohenthauer, *Secretary/Word Processor Specialist*

Carol Guntow, *Clerical Assistant*

Advisory Panel for Federal Policies and the Medical Devices Industry

Richard R. Nelson, *Chair*
Institute for Social and Policy Studies, Yale University
New Haven, CT

William F. Ballhaus
International Numatics, Inc.
Beverly Hills, CA

Ruth Farrisey
Massachusetts General Hospital
Boston, MA

Peter Barton Hutt
Covington & Burling
Washington, DC

Alan R. Kahn
Consultant
Cincinnati, OH

Grace Kraft
Kidney Foundation of the Upper Midwest
Cannon Falls, MN

Joyce Lashof
School of Public Health
University of California
Berkeley, CA

Penn Lupovich
Group Health Association
Washington, DC

Victor McCoy
Paralyzed Veterans of America
Washington, DC

Robert M. Moliter
Medical Systems Division
General Electric Co.
Washington, DC

Louise B. Russell
The Brookings Institution
Washington, DC

Earl J. Saltzgiver
Foremost Contact Lens Service, Inc.
Salt Lake City, UT

Rosemary Stevens
Department of History and Sociology of Science
University of Pennsylvania
Philadelphia, PA

Allan R. Thieme
Amigo Sales, Inc.
Albuquerque, NM

Eric von Hippel
Sloan School
Massachusetts Institute of Technology
Cambridge, MA

Edwin C. Whitehead
Technicon Corp.
Tarrytown, NY

Technology and Aging in America Advisory Panel*

Robert Binstock, *Panel Chair*
Director, Policy Center on Aging, Brandeis University

Raymond Bartus
Group Leader of Geriatrics
Medical Research Division
Lederle Laboratories

Robert Berliner
Dean
School of Medicine
Yale University

Robert N. Butler
Chairman
Department of Geriatrics and Adult Education
Mt. Sinai Medical Center

Robert Clark
Associate Professor
Department of Economics and Business
North Carolina State University

Lee L. Davenport
Senior Vice President-Chief Scientist, emeritus
GTE Corp.

Ken Dychtwald
President
Dychtwald & Associates

Caleb Finch
Professor of Biological Sciences and Gerontology
University of Southern California

Velma Murphy Hill
Director
Civil and Human Rights Division
Service Employees International Union

Robert L. Kane
Senior Researcher
The Rand Corp.

Paul A. Kerschner
Associate Director for Programs, Legislation
and Development
American Association of Retired Persons

Maggie Kuhn
Founder and National Convener
The Gray Panthers

Matt Lind
Vice President
Corporate Planning and Research
The Travelers Insurance Co.

Robert G. Lynch
Vice President
Marketing Planning
GTE Corp.

Mathy D. Mezey
Director
Teaching Nursing Home Program
University of Pennsylvania

Hamish Munro
Professor of Medicine and Nutrition
Tufts University

Bernice Neugarten
Professor of Education and Sociology
Northwestern University

Sara Rix
Director of Research
The Women's Research and Education Institute

Pauline Robinson
Research Professor of Gerontology
University of Southern California

John W. Rowe
Chief of Geriatrics
Beth Israel Hospital

Bert Seidman
Director
Department of Occupational Safety, Health
and Social Security
AFL-CIO

Jacob Siegel
Senior Researcher
Center for Population Research
Georgetown University

*Panel members' affiliations are listed at the time the assessment began

NOTE: OTA appreciates and is grateful for the valuable assistance and thoughtful critiques provided by the advisory panel members. The views expressed in this OTA report, however, are the sole responsibility of the Office of Technology Assessment.